Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients

This study has been completed.

Sponsored by:	Sheba Medical Center
Information provided by:	Sheba Medical Center
ClinicalTrials.gov Identifier:	NCT00234689

Purpose

Assessing the efficacy of Naltrexone as augmentation to SSRI in patients with OCD

Condition	Intervention
Obsessive Compulsive Disorder	Drug: Naltrexone

MedlinePlus related topics: Obsessive-Compulsive Disorder

Drug Information available for: Naltrexone Naltrexone hydrochloride

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Placebo Control, Crossover Assignment

Further study details as provided by Sheba Medical Center:

Study Start Date:	January 2002
Study Completion Date:	December 2004
Primary Completion Date:	December 2004 (Final data collection date for primary outcome measure)

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00234689

Locations

Sponsors and Collaborators

Sheba Medical Center

Investigators

Principal Investigator:	Joseph Zohar, MD	Tel Aviv University
Study Chair:	Revital Amiaz, MD	Tel Aviv University

More Information

Responsible Party:	Chaim Sheba Medical Center ( Prof. Joseph Zohar )
Study ID Numbers:	SHEBA-99-1897-JZ-CTIL
Study First Received:	October 6, 2005
Last Updated:	January 28, 2008
ClinicalTrials.gov Identifier:	NCT00234689
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:

Anxiety Disorders
Mental Disorders
Naltrexone
Obsessive-Compulsive Disorder

Additional relevant MeSH terms:

Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Narcotic Antagonists

Peripheral Nervous System Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009